UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 25, 2011
HELIX BIOMEDIX, INC.
(Exact name of registrant as specified in its charter)
|
DELAWARE
|
033-20897-D
|
91-2099117
|
|
(State or other jurisdiction
of incorporation or organization)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
22118 20th Avenue S.E., Suite 204
Bothell, Washington 98021
(425) 402-8400
(Address and telephone number of registrant’s principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
On August 25, 2011, Helix BioMedix, Inc. (the “Company”) entered into a Second Amendment to License Agreement (the “Amendment”) with Rodan & Fields, LLC (“R+F”), pursuant to which the parties agreed to extend the term of the License Agreement between the Company and R+F dated August 27, 2008, as amended (the “License Agreement”), from three to four years unless otherwise terminated in accordance with the terms and conditions of the License Agreement and to amend the automatic one-year renewal provision to eliminate R+F’s minimum royalty payment obligation as a condition precedent thereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
HELIX BIOMEDIX, INC.
|
||||
|
Dated: August 29, 2011
|
By:
|
/s/ R. Stephen Beatty
|
||
|
R. Stephen Beatty
|
||||
|
President and Chief Executive Officer
|
||||